China’s military last month received the greenlight to use a COVID-19 vaccine candidate, Ad5-nCoV, developed by its research unit and CanSino Biologics.
The Ad5-nCoV is one of China’s eight vaccine candidates approved for human trials at home and abroad for the respiratory disease caused by the new coronavirus. The shot also won approval for human testing in Canada.
China’s Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a filing. The vaccine candidate was developed jointly by CanSino and a research institute at the Academy of Military Science (AMS).
Here is what you need to know about Ad5-nCoV- CanSino’s COVID-19 vaccine candidate
The vaccine candidate is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform, which has also been successfully applied to develop the globally innovative vaccine against Ebola virus infection.
Incorporated in 2009, CanSinoBIO commits to research, production and commercialization of innovative vaccines for China and global public health security.
It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation.
As of today, it has established a robust pipeline of 16 vaccines covering 13 diseases, including a globally innovative Ebola virus vaccine approved for marketing in 2017.